http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
정재연 ( Jae Youn Cheong ) 대한간학회 2006 간학회 싱글토픽 심포지움 Vol.12 No.4
Progressive hepatic fibrosis with development of cirrhosis is a feature of almost all chronic liver diseases. As novel therapies for liver fibrosis evolve, non-invasive measurement of liver fibrosis will be required to help management of patients with chronic liver disease. An ideal noninvasive diagnostic test for hepatic fibrosis should be simple, inexpensive and accurate. Although liver biopsy is the current gold standard for the diagnosis of liver fibrosis, it is invasive, stressful and subject to sampling error. Here we will review our current knowledge of methods used to assess both the stage of fibrosis and the activity of extracellular matrix turnover, and we discuss the radiological and serum tests that have been proposed as potential alternatives to liver biopsies. We discuss the indirect markers of liver fibrosis that reflect alterations in liver function or inflammation well be discussed. Future trends for staging liver disease must not only focus on cross sectional diagnosis, but on utilizing novel techniques to stratify the risk for disease progression over time.
간문맥 혈전이 동반된 진행성 간세포암에서 간동맥내 항암제 주입요법
정재연 ( Jae Youn Cheong ),이기명 ( Kee Myung Lee ),조성원 ( Sung Won Cho ),원제환 ( Jae Han Won ),김재근 ( Jai Keun Kim ),왕희정 ( Hee Jung Wang ),함기백 ( Ki Baik Hahm ),김진홍 ( Jin Hong Kim ) 대한내과학회 2004 대한내과학회지 Vol.67 No.1
목적: 간문맥 혈전이 동반된 간세포암은 예후가 매우 불량한 것으로 알려져 있다. 경간동맥 화학색전술은 진행성 간세포암의 치료로 널리 행해지고 있으나 일부 환자에서는 치료 후 간부전이 문제시 된다. 본 연구는 간문맥 혈전이 동반된 진행성 간세포암에서 보존적 치료 및 전신적 항암 요법과 비교하여 간동맥내 5-fluorouracil (FU), cisplatin 주입요법의 치료 효과를 알아보고, 생존에 영향을 미치는 예후인자를 알아보고자 하였다. 방법: 199 Background: Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis has a poor prognosis and has little hope for meaningful therapy. Transarterial chemoembolization has been performed as a treatment for advanced HCC, but some patients die from
정재연 ( Jae Youn Cheong ) 대한소화기학회 2017 대한소화기학회지 Vol.70 No.5
Cirrhotic patients have bleeding tendencies due to the lack of coagulation factors and thrombocytopenia. However, decreased levels of procoagulants are also accompanied by decreased levels of natural anticoagulants. However, there have been contrasting reports. It has been reported that patients with cirrhosis are at risk for thrombotic complications, including portal vein thrombosis and venous thromboembolism. Physicians consider active anticoagulation for prophylaxis and treatment of portal vein thrombosis and/or venous thromboembolism in cirrhotic patients with high risk of thrombosis. Concurrently, there are safety concerns regarding the risk of bleeding from anticoagulants in people with advanced liver disease. Further prospective studies are required to determine not only if cirrhotic patients benefit from receiving anticoagulation therapy for preventing thrombotic complications, but also to determine which prophylactic regimen is most appropriate. (Korean J Gastroenterol 2017;70:218-222)